Magnetic Resonance Imaging (MRI) is a cornerstone of neuroimaging for neurodegenerative diseases, providing detailed anatomical, structural, and increasingly functional information about the living brain. MRI is essential for diagnosing Alzheimer's disease, Parkinson's disease, and atypical parkinsonian syndromes, as well as for monitoring disease progression and evaluating therapeutic responses.
The most commonly used technique, providing detailed anatomy:
- Gray matter assessment: Hippocampal atrophy, cortical thinning
- White matter evaluation: Lesion detection, tract integrity
- Volumetric analysis: Regional brain volume measurements
- Clinical use: AD diagnosis, disease staging
- Fluid-attenuated inversion recovery (FLAIR): White matter hyperintensities
- T2 hyperintensities: Demyelination, gliosis, edema
- Clinical utility: Vascular changes, white matter disease
- Iron deposition: Quantification of brain iron accumulation
- Microhemorrhages: Cerebral microbleed detection
- Calcification: Basal ganglia and other calcifications
- Utility in: NBIA, Parkinson's disease, MSA
Measures water molecule motion, sensitive to microstructural changes:
- Fractional anisotropy (FA): White matter integrity
- Mean diffusivity (MD): Overall diffusion magnitude
- Tractography: White matter tract reconstruction
- Clinical applications:
- Parkinson's disease: Nigrostriatal pathway changes](/proteins/parkin)
- FTD: Frontotemporal tract involvement
| Technique |
Information Gained |
Clinical Application |
| Q-ball imaging |
Multiple fiber populations |
Crossing fiber regions |
| NODDI |
Neurite density |
Microstructural integrity |
| Diffusion kurtosis |
Non-Gaussian diffusion |
Tissue heterogeneity |
Measures blood oxygen level-dependent (BOLD) signal:
- Default mode network: Functional connectivity changes
- Disease-specific patterns: Network breakdown in AD, PD
- Presymptomatic detection: Connectivity changes before atrophy
- Cognitive activation: Memory, executive function testing
- Motor activation: Finger tapping, gait paradigms
- Clinical research: Treatment effects on brain activity
Measures cerebral blood flow:
- Non-contrast: No radiation, repeatable
- Cerebral blood flow: Quantitative measurements
- Applications: CBS, PSP, dementia subtypes
Measures metabolite concentrations:
| Metabolite |
Significance |
| N-acetylaspartate (NAA) |
Neuronal viability |
| Choline |
Membrane turnover |
| Creatine |
Energy metabolism |
| Myo-inositol |
Glial marker |
| Lactate |
Metabolic stress |
MRS applications in neurodegeneration:
- Alzheimer's: Reduced NAA, elevated myo-inositol
- Parkinson's: NAA changes in substantia nigra
- Dementia: Metabolic profiling for differential diagnosis
- Hippocampal atrophy: Most sensitive early marker
- Entorhinal cortex thinning: Precedes hippocampal changes
- Posterior cingulate: Early hypometabolism
- Cortical thinning: Temporal, parietal, frontal regions
- Ventricular enlargement: Secondary to parenchymal loss
- Default mode network disruption: Early functional disconnectivity
- Posterior cingulate hypoperfusion: Characteristic pattern
- Reduced hippocampal connectivity: Memory network dysfunction
- Substantia nigra pars compacta: Loss of neuromelanin signal
- Red nucleus changes: Related to akinesia
- Pontine and cerebellar changes: In parkinsonian variants
- Levodopa-induced changes: Long-term treatment effects
- Neuromelanin-sensitive MRI: Loss of signal in substantia nigra
- Iron-sensitive imaging (R2, SWI)*: Increased iron deposition
- Diffusion changes: In substantia nigra and striatum
- Resting-state fMRI: Altered connectivity patterns
- Midbrain atrophy: "Hummingbird sign" on sagittal MRI
- Superior cerebellar peduncle: Signal changes
- Red nucleus: T2 hypointensity
- Third ventricle: Dilatation
- MR parkinsonism index: Elevated in PSP vs. PD
- Brainstem/cerebellar atrophy: "Hot cross bun" sign
- Putaminal atrophy: Hyperintense putaminal rim
- Cerebellar atrophy: In MSA-C variant
- Middle cerebellar peduncle: T2 hyperintensity
- Asymmetric cortical atrophy: Frontoparietal regions
- Basal ganglia: T2 changes
- Corpus callosum: Thinning, especially anterior
- Central atrophy: Brainstem involvement
| Variant |
MRI Findings |
| Behavioral variant FTD |
Frontal and anterior temporal atrophy |
| Semantic dementia |
Left > right anterior temporal atrophy |
| Nonfluent/agrammatic PPA |
Left perisylvian atrophy |
| Logopenic PPA |
Left posterior temporal and parietal atrophy |
- White matter lesions: Confluent hyperintensities on FLAIR
- Lacunes: Small subcortical infarcts
- Microbleeds: Especially in amyloid angiopathy
- Cortical infarcts: Territorial infarcts
- Relative preservation: Less hippocampal atrophy than AD
- Occipital hypoperfusion: Characteristic finding
- Dorsal midbrain: Signal changes
- Temporal lobe: Less affected than AD
| Region |
AD |
PD |
PSP |
MSA |
| Hippocampus |
↓↓ |
↓ |
↓ |
↓ |
| Brainstem |
↓ |
↓ |
↓↓ |
↓ |
| Cerebellum |
- |
- |
↓ |
↓↓ |
| Putamen |
↓ |
↓ |
↓ |
↓↓ |
| Cortex |
↓↓ |
↓ |
↓ |
↓ |
- MTA scale (Medial Temporal Atrophy): 0-4 scale for hippocampal atrophy
- Fazekas scale: White matter hyperintensity grading
- Koedam score: Posterior atrophy scoring
- DTI in AD: Reduced FA in major white matter tracts
- DTI in PD: Changes in substantia nigra, white matter
- DTI in PSP: Superior cerebellar peduncle involvement
- Initial evaluation: Rule out secondary causes
- Differential diagnosis: AD vs. FTD vs. Lewy body dementia
- Atypical parkinsonism: Distinguish MSA, PSP, CBS from PD
- Progression monitoring: Annual volumetric assessments
- Clinical trials: Enrollment criteria, outcome measures
- Biomarker development: Early detection, disease progression
- Treatment monitoring: Disease-modifying therapy effects
- Neuropathology correlation: In vivo pathology assessment
| Field Strength |
Advantages |
Disadvantages |
| 1.5T |
Widely available, lower cost |
Limited resolution |
| 3T |
Standard for research, good resolution |
Higher cost |
| 7T |
Ultra-high resolution research |
Limited availability |
- T1-weighted (MPRAGE/IR-SPGR): 1mm isotropic
- T2-weighted/FLAIR: 3mm slices
- SWI: 1mm isotropic
- DTI: 2mm isotropic, 30+ directions
- Optional: ASL, MRS
- FreeSurfer: Cortical parcellation, volumetric analysis
- FSL: Diffusion analysis, tractography
- ANTs: Image registration, normalization
- SPM/FSL: Statistical parametric mapping
- BrainSuite: Surface-based analysis
- Increased signal: Higher SNR for detailed imaging
- Improved resolution: Sub-millimeter imaging possible
- Susceptibility contrast: Enhanced SWI, QSM
- Clinical research: Detecting early changes
- Iron quantification: Direct measurement of brain iron
- Myelin imaging: Contrast from magnetic susceptibility
- Clinical potential: Parkinson's, MSA, NBIA
- Automated analysis: Rapid image processing
- Classification: AD vs. normal vs. FTD
- Prediction: Converted MCI to AD
- Radiomics: Feature extraction for diagnosis
- Motion artifact: Especially in dementia patients
- Partial volume: Small structure resolution
- Scan time: Trade-offs between resolution and time
- Standardization: Between-scanner variability
- Lack of specificity: Similar atrophy patterns
- Late detection: Changes occur after symptoms
- Cost: MRI is expensive compared to CT
- Access: Not all facilities have MRI